Research ExplorerPublicationsAbundant expression of mTOR kinase in salivary gland tumors ...

Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target?

Standard

Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target? / Clauditz, Till Sebastian; Gontarewicz, Artur; Bokemeyer, Carsten; Sauter, Guido; Knecht, Rainald; Münscher, Adrian; Wilczak, Waldemar.

In: J ORAL PATHOL MED, Vol. 42, No. 10, 01.11.2013, p. 769-73.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Clauditz, TS, Gontarewicz, A, Bokemeyer, C, Sauter, G, Knecht, R, Münscher, A & Wilczak, W 2013, 'Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target?', J ORAL PATHOL MED, vol. 42, no. 10, pp. 769-73. https://doi.org/10.1111/jop.12064

APA

Clauditz, T. S., Gontarewicz, A., Bokemeyer, C., Sauter, G., Knecht, R., Münscher, A., & Wilczak, W. (2013). Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target? J ORAL PATHOL MED, 42(10), 769-73. https://doi.org/10.1111/jop.12064

Vancouver

Clauditz TS, Gontarewicz A, Bokemeyer C, Sauter G, Knecht R, Münscher A et al. Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target? J ORAL PATHOL MED. 2013 Nov 1;42(10):769-73. https://doi.org/10.1111/jop.12064

Bibtex

@article{d8bc285e0dcb4218ba308f9d4275781b,
title = "Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target?",
abstract = "BACKGROUND: Salivary gland tumors constitute 3-6% of all head and neck neoplasms in adults. Because of limited advances made in the treatment of metastatic disease, the more important is the role of new therapeutic strategies, including molecular therapy. The mammalian target of rapamycin (mTOR) has recently been established as a therapeutic target for several drugs.MATERIAL: Evaluation of phospho-mTOR as a possible therapy target by patients with salivary gland tumors. Immunohistochemical semi-quantitative analyses of the expression of phospho-mTOR(Ser2448) were processed on a tissue microarray containing samples from more than 900 patients. For statistical analysis, contingency table and chi-squared test (likelihood) were used.RESULTS: We observed at least weak phospho-mTOR expression in 25.6-41.2% of all 4 histological adenoma and in 36.8-61.6% of all 11 histological carcinoma subtypes analyzed. No association was seen between phospho-mTOR expression and tumor grade in mucoepidermoid carcinomas.CONCLUSION: In conjunction with literature data providing the evidence for a functional role of mTOR in salivary gland tumors, we conclude that treatment with mTOR-antagonists might potentially also be efficient in wide variety of salivary gland carcinomas.",
author = "Clauditz, {Till Sebastian} and Artur Gontarewicz and Carsten Bokemeyer and Guido Sauter and Rainald Knecht and Adrian M{\"u}nscher and Waldemar Wilczak",
note = "{\textcopyright} 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2013",
month = nov,
day = "1",
doi = "10.1111/jop.12064",
language = "English",
volume = "42",
pages = "769--73",
journal = "J ORAL PATHOL MED",
issn = "0904-2512",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target?

AU - Clauditz, Till Sebastian

AU - Gontarewicz, Artur

AU - Bokemeyer, Carsten

AU - Sauter, Guido

AU - Knecht, Rainald

AU - Münscher, Adrian

AU - Wilczak, Waldemar

N1 - © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - BACKGROUND: Salivary gland tumors constitute 3-6% of all head and neck neoplasms in adults. Because of limited advances made in the treatment of metastatic disease, the more important is the role of new therapeutic strategies, including molecular therapy. The mammalian target of rapamycin (mTOR) has recently been established as a therapeutic target for several drugs.MATERIAL: Evaluation of phospho-mTOR as a possible therapy target by patients with salivary gland tumors. Immunohistochemical semi-quantitative analyses of the expression of phospho-mTOR(Ser2448) were processed on a tissue microarray containing samples from more than 900 patients. For statistical analysis, contingency table and chi-squared test (likelihood) were used.RESULTS: We observed at least weak phospho-mTOR expression in 25.6-41.2% of all 4 histological adenoma and in 36.8-61.6% of all 11 histological carcinoma subtypes analyzed. No association was seen between phospho-mTOR expression and tumor grade in mucoepidermoid carcinomas.CONCLUSION: In conjunction with literature data providing the evidence for a functional role of mTOR in salivary gland tumors, we conclude that treatment with mTOR-antagonists might potentially also be efficient in wide variety of salivary gland carcinomas.

AB - BACKGROUND: Salivary gland tumors constitute 3-6% of all head and neck neoplasms in adults. Because of limited advances made in the treatment of metastatic disease, the more important is the role of new therapeutic strategies, including molecular therapy. The mammalian target of rapamycin (mTOR) has recently been established as a therapeutic target for several drugs.MATERIAL: Evaluation of phospho-mTOR as a possible therapy target by patients with salivary gland tumors. Immunohistochemical semi-quantitative analyses of the expression of phospho-mTOR(Ser2448) were processed on a tissue microarray containing samples from more than 900 patients. For statistical analysis, contingency table and chi-squared test (likelihood) were used.RESULTS: We observed at least weak phospho-mTOR expression in 25.6-41.2% of all 4 histological adenoma and in 36.8-61.6% of all 11 histological carcinoma subtypes analyzed. No association was seen between phospho-mTOR expression and tumor grade in mucoepidermoid carcinomas.CONCLUSION: In conjunction with literature data providing the evidence for a functional role of mTOR in salivary gland tumors, we conclude that treatment with mTOR-antagonists might potentially also be efficient in wide variety of salivary gland carcinomas.

U2 - 10.1111/jop.12064

DO - 10.1111/jop.12064

M3 - SCORING: Journal article

C2 - 23521157

VL - 42

SP - 769

EP - 773

JO - J ORAL PATHOL MED

JF - J ORAL PATHOL MED

SN - 0904-2512

IS - 10

ER -